Endpoint surrogacy in oncology Phase 3 randomised controlled trials.
Jianrong ZhangMeagan R PilarXiaofei WangJingxia LiuHerbert PangRoss C BrownsonGraham A ColditzWenhua LiangJianxing HePublished in: British journal of cancer (2020)
Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.